ORAMED PHARMACEUTICALS INC (ORMP) — insider trading
Health Care · NASDAQ
ORAMED PHARMACEUTICALS INC (ORMP) has 39 reported SEC Form 4 insider transactions in our data, including 4 open-market sales among the most recent 39 (latest 2026-10-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Hexter Joshua | Officer (COO & CBO) | Open-market sale | 30,000 | $4.51 | $135.3K | Form 4 |
| 2026-10-01 | Gabay Avraham | Officer (Chief Financial Officer) | Open-market sale | 20,000 | $4.51 | $90.2K | Form 4 |
| 2026-09-24 | Gabay Avraham | Officer (Chief Financial Officer) | Grant / award / vesting | 209,291 | — | — | Form 4 |
| 2026-09-24 | Kidron Miriam | Director, Officer (Chief Scientific Officer) | Disposition to the issuer (derivative) | 72,000 | — | — | Form 4 |
| 2026-09-24 | Kidron Miriam | Director, Officer (Chief Scientific Officer) | Disposition to the issuer (derivative) | 100,000 | — | — | Form 4 |
| 2026-09-24 | Kidron Miriam | Director, Officer (Chief Scientific Officer) | Disposition to the issuer (derivative) | 47,000 | — | — | Form 4 |
| 2026-09-24 | Kidron Miriam | Director, Officer (Chief Scientific Officer) | Disposition to the issuer (derivative) | 69,999 | — | — | Form 4 |
| 2026-09-24 | Kidron Miriam | Director, Officer (Chief Scientific Officer) | Disposition to the issuer (derivative) | 100,000 | — | — | Form 4 |
| 2026-09-24 | Kidron Miriam | Director, Officer (Chief Scientific Officer) | Disposition to the issuer (derivative) | 104,000 | — | — | Form 4 |
| 2026-09-24 | Kidron Miriam | Director, Officer (Chief Scientific Officer) | Grant / award / vesting | 209,291 | — | — | Form 4 |
| 2026-09-24 | Kidron Miriam | Director, Officer (Chief Scientific Officer) | Grant / award / vesting | 208,125 | — | — | Form 4 |
| 2026-09-24 | Hexter Joshua | Officer (COO & CBO) | Disposition to the issuer (derivative) | 36,000 | — | — | Form 4 |
| 2026-09-24 | Hexter Joshua | Officer (COO & CBO) | Disposition to the issuer (derivative) | 50,000 | — | — | Form 4 |
| 2026-09-24 | Hexter Joshua | Officer (COO & CBO) | Disposition to the issuer (derivative) | 50,000 | — | — | Form 4 |
| 2026-09-24 | Hexter Joshua | Officer (COO & CBO) | Grant / award / vesting | 209,291 | — | — | Form 4 |
| 2026-09-24 | Hexter Joshua | Officer (COO & CBO) | Grant / award / vesting | 75,455 | — | — | Form 4 |
| 2026-09-24 | KIDRON NADAV | Director, Officer (President and CEO) | Disposition to the issuer (derivative) | 107,000 | — | — | Form 4 |
| 2026-09-24 | KIDRON NADAV | Director, Officer (President and CEO) | Disposition to the issuer (derivative) | 150,000 | — | — | Form 4 |
| 2026-09-24 | KIDRON NADAV | Director, Officer (President and CEO) | Disposition to the issuer (derivative) | 97,000 | — | — | Form 4 |
| 2026-09-24 | KIDRON NADAV | Director, Officer (President and CEO) | Disposition to the issuer (derivative) | 49,000 | — | — | Form 4 |
| 2026-09-24 | KIDRON NADAV | Director, Officer (President and CEO) | Disposition to the issuer (derivative) | 190,000 | — | — | Form 4 |
| 2026-09-24 | KIDRON NADAV | Director, Officer (President and CEO) | Disposition to the issuer (derivative) | 196,500 | — | — | Form 4 |
| 2026-09-24 | KIDRON NADAV | Director, Officer (President and CEO) | Grant / award / vesting | 368,765 | — | — | Form 4 |
| 2026-09-24 | KIDRON NADAV | Director, Officer (President and CEO) | Grant / award / vesting | 349,497 | — | — | Form 4 |
| 2026-07-02 | Hexter Joshua | Officer (COO & CBO) | Option exercise / conversion (derivative) | 50,000 | — | $0 | Form 4 |
| 2026-07-02 | Hexter Joshua | Officer (COO & CBO) | Option exercise / conversion | 50,000 | $3.69 | $184.5K | Form 4 |
| 2026-07-01 | Gabay Avraham | Officer (Chief Financial Officer) | Open-market sale | 73,360 | $4.51 | $330.7K | Form 4 |
| 2026-07-01 | Hexter Joshua | Officer (COO & CBO) | Open-market sale | 137,000 | $4.46 | $611.4K | Form 4 |
| 2026-03-30 | Kidron Miriam | Director, Officer (Chief Scientific Officer) | Shares withheld for taxes / exercise cost | 435,084 | $3.31 | $1.44M | Form 4 |
| 2026-03-30 | KIDRON NADAV | Director, Officer (President and CEO) | Shares withheld for taxes / exercise cost | 44,818 | $3.31 | $148.3K | Form 4 |
| 2026-03-17 | Gabay Avraham | Officer (Chief Financial Officer) | Grant / award / vesting | 95,889 | — | $0 | Form 4 |
| 2026-03-17 | Hexter Joshua | Officer (COO & CBO) | Grant / award / vesting | 95,889 | — | $0 | Form 4 |
| 2026-03-17 | KIDRON NADAV | Director, Officer (President and CEO) | Grant / award / vesting | 167,005 | — | $0 | Form 4 |
| 2026-03-17 | Kidron Miriam | Director, Officer (Chief Scientific Officer) | Grant / award / vesting | 119,558 | — | $0 | Form 4 |
| 2026-03-12 | KIDRON NADAV | Director, Officer (President and CEO) | Bona fide gift | 100,000 | — | $0 | Form 4 |
| 2026-01-22 | Kidron Miriam | Director, Officer (Chief Scientific Officer) | Option exercise / conversion (derivative) | 19,000 | — | $0 | Form 4 |
| 2026-01-22 | Kidron Miriam | Director, Officer (Chief Scientific Officer) | Option exercise / conversion | 19,000 | — | $0 | Form 4 |
| 2026-01-22 | Hexter Joshua | Officer (COO & CBO) | Option exercise / conversion (derivative) | 19,000 | — | $0 | Form 4 |
| 2026-01-22 | Hexter Joshua | Officer (COO & CBO) | Option exercise / conversion | 19,000 | — | $0 | Form 4 |
Ask the chat about ORMP's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ORAMED PHARMACEUTICALS INC (ORMP).
Last updated 2026-10-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.